Glooko and Hedia Unite to Transform Diabetes Management with Personalized Insulin Dosing

Glooko and Hedia Team Up for Enhanced Diabetes Management

In a groundbreaking announcement, Glooko, Inc. and Hedia have unveiled their interoperable solution that promises to elevate diabetes treatment for patients with both Type 1 and Type 2 diabetes. This innovative platform integrates connected care, remote patient monitoring, and digital therapy to offer crucial support for informing bolus insulin dosing, essential for effective diabetes management. Currently available in the UK, this solution is set to roll out across other European countries in the coming months.

Understanding Bolus Insulin Dosing

Bolus insulin doses are vital for controlling blood sugar levels, particularly during meals or snacks when glucose levels are likely to spike. Generally, a single unit of insulin is estimated to lower blood sugar by 50 mg/dl, although individual needs can vary significantly. For diabetes patients who do not utilize an insulin pump, determining the correct bolus dose can be a challenging task, requiring careful consideration and calculation that often involves both the patient and the healthcare provider.

Glooko’s platform provides a seamless means for patients to share their diabetes-related data with healthcare providers, including blood sugar readings, insulin doses, carbohydrate intake, physical activity, and other vital statistics such as blood pressure and weight. The collaboration with Hedia enhances the Glooko platform by delivering tailored support to help users calculate precise insulin doses, thereby simplifying diabetes management and promoting stable blood sugar levels.

This integrated approach not only streamlines the management of multiple daily injections (MDI) but also aims to improve health outcomes for both patients and their providers, offering better insights into patient health data. The availability of accessible blood sugar data, insulin doses, carbohydrate consumption, and physical activity offers healthcare professionals a holistic view of their patients' health.

A Statement From Glooko’s CEO

Mike Alvarez, CEO of Glooko, expressed enthusiasm for the partnership, stating, “We are thrilled to introduce this algorithm-driven, personalized innovation for diabetes patients and their healthcare providers through our collaboration with Hedia. Supported by extensive clinical data attesting to Hedia’s effectiveness, this solution acts as an alternative for those without insulin pumps, ensuring more effective MDI management.” He emphasized that this partnership underscores Glooko's commitment to developing digital health tools that not only optimize diabetes treatment but also aid in stabilizing blood sugar levels through personalized, connected care.

Hedia’s Vision and Compliance

Lars Christian Lund, CEO of Hedia, also shared his excitement regarding this collaboration, noting, “We are eager to work alongside Glooko, a company noted for its broad clinical network. This joint offering aligns perfectly with Hedia's mission to enhance the quality of life for diabetes patients by equipping them with the best tools for diabetes management.” Lund highlighted the focus on regulatory compliance in their technology development, stating that Hedia has recently received MDR certification in Europe. The company's classification as a Class IIb medical device aims at ensuring that patients and caregivers gain access to the most suitable solutions.

About Hedia and Glooko

Hedia stands as a leading digital treatment company dedicated to empowering individuals with insulin-dependent diabetes to take control of their condition. The foundation of Hedia’s diabetes application is its ability to offer insulin recommendations based on individual habits and preferences, factoring in numerous aspects of diabetes management such as tracking blood sugar readings and monitoring carbohydrate intake.

Glooko positions itself as a pioneer in improving health outcomes for those with chronic conditions through its intelligent, connected care and life sciences platform. With its robust technology, Glooko seeks to enhance the patient-provider connection, encourage patient engagement, and streamline clinical trials. Currently, Glooko operates in more than 30 countries and has been utilized by over 4.4 million users.

For further information, visit Glooko's website.